NEO TECT KIT
LOE ApproachingPeptidetechnetium tc-99m depreotide
NDAINJECTIONINJECTABLEPriority Review
Approved
Aug 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 3h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEO TECT KIT is a technetium TC-99m labeled radiopharmaceutical diagnostic agent used for scintigraphic imaging. It is a small-molecule radioisotope injection designed to localize somatostatin receptors in the body. The product enables non-invasive detection and visualization of neuroendocrine tumors and other somatostatin receptor-positive lesions.
LOE Approaching
LOE approaching signals consolidation phase; expect smaller, specialized commercial teams focused on existing customer relationships rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NEO TECT offers exposure to specialized diagnostics and niche oncology imaging markets, but limited career upside given LOE approaching status and zero linked job openings. Career development will emphasize customer retention, operational excellence, and transition planning rather than growth or innovation.
Product ManagerMedical Science Liaison
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.